Mechanisms, DefenseNCT04018066
The Effect of Concord Grape Polyphenol-soy Protein Isolate Complex (GP-SPI) on Gut Microbiota
A study testing GP-SPI in people with Mechanisms, Defense, run by Rutgers, The State University of New Jersey at 1 site in United States.
Trial summary
The overall purpose of this study is to evaluate the effect of nutritional supplementation with a well-characterized preparation of Concord grape polyphenol-soy protein isolate (GP-SPI) on the composition of the gut microbiota. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Mechanisms, Defense
- What is being tested?
- GP-SPI
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Jun 2019to 20 Dec 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy as assessed based on a medical evaluation including a comprehensive metabolic panel (CMP) test with values in normal range, medical history and not presently taking any medication
- Adults between 18 and 35 years
- BMI 18.5 -29.9
- Have at least one bowel movement per day
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Who cannot join
- History/current cancer, rheumatoid arthritis immunologic, renal, hepatic, endocrine, neurologic or heart disease, hypertension, diabetes, GI dysfunction, or CMP test results showing values outside of normal range.
- Cannot provide written informed consent.
- Exposure to any experimental agent or procedure within 30 days of study.
- Pregnancy or breast-feeding
- Taking dietary supplements
- Current smoker or have smoked within previous 6 months
Show all 9Show fewer
- Taking medications regularly (prescription, over the counter, supplements etc.)
- Treated with antibiotics during the past 6 months
- Have an allergy to soy or grapes
Trial locations and contacts
1 site in 1 country.
United States1 site
Rutgers, The State University of New Jersey
New Brunswick, New Jersey, 08901
About this study
The overall purpose of this study is to evaluate the effect of nutritional supplementation with a well-characterized preparation of Concord grape polyphenol-soy protein isolate (GP-SPI) on the composition of the gut microbiota.
Read the detailed description
The proposed study will investigate how short-term supplementation with GP-SPI may modify the gut microbial community in healthy participants while monitoring liver and kidney function/health.
Significance:
Biochemical properties of the GP-SPI food ingredient are well-documented and GP-SPI and SPI supplements have been tested extensively in mice. The proposed study is a logical follow up to animal studies, which showed that compared to control mice fed a high-fat diet (HFD) supplemented with SPI alone, mice fed an isocaloric HFD supplemented with GP-SPI exhibited greater resistance to weight gain, adiposity, and glucose intolerance. These effects were accompanied by changes in murine gut microbiota composition, including increased abundance of the microbe Akkermansia muciniphila, associated with metabolic resilience. Similar gut microbiota changes were observed in lean mice fed low-fat diet (LFD) supplemented with GP-SPI.
The B-type proanthocyanidin (PAC) class of polyphenols contained in grape berries, especially skins and seeds, have been associated with health benefits; however, PACs are poorly absorbed and reach high concentration only in the colon raising questions about mechanism(s) of action. Prior studies showed that dietary PACs from grape and cranberry alter the gut microbiota in association with metabolic resilience. PACs are also biotransformed by gut bacteria to yield microbial metabolites (MMs) that may contribute to health benefits.
Research Design and Methods
Prospective participants will be recruited through flyers posted locally on Rutgers University campuses and sent to university email lists. Interested persons will be screened according to inclusion and exclusion criteria.
Enrolled subjects will begin the 17-day study.
Study Procedures
- Thirty subjects will be enrolled.
- Food List: Participants will maintain their usual diet except for a provided list of PAC-rich foods that they will be asked to abstain from for a 5-day wash-out period and during the 10-day intervention. The Food List is provided below. The goal is to have GP-SPI as the main/only source of PAC in the diet for the study period.
- Wash-out and SPI (Day -5 through -1): On day -5 (pre-baseline) before any supplementation, each subject will collect their fecal and urine sample. Each subject will then consume SPI twice a day (provided as pre-weighed packets of 20 g) during a 5-day wash-out period (days -5, -4, -3, -2, and -1). Subjects will be instructed to mix each packet of SPI in 250 mL of water or in a smoothie (recipe example below will be provided) using allowed foods as detailed in instructions and consume once in the morning before breakfast and once in the evening before dinner.
- Day 0: On the following day each subject will collect their baseline (day 0) stool and urine samples. They will have a blood sample drawn by a study nurse. Blood will be used for CMP test and prepared serum will be aliquoted and stored at -80 °C until processing for marker analysis and metabolomics. Analysis of day 0 samples should help isolate any effects due to SPI alone from subsequent samples collected during GP-SPI intervention. On day 0 subjects will drop off urine and stool samples at IFNH and collect GP-SPI packets. On Day 0 participants will also take a break from consuming SPI and will start GP-SPI supplementation on morning of Day 1.
- GP-SPI (Day 1 - 10): Each subject will receive twenty pre-weighed 20 g packets of GP-SPI. On day 1 subjects will be instructed to mix each packet of GP-SPI in 250 mL of water or in smoothie (recipe example will be provided, please see below) using allowed foods as detailed in instructions and consume the GP-SPI mix once in the morning before breakfast and once in the evening before dinner for 10 consecutive days.
- Subjects will be provided with a personal blender for smoothie preparation (value ~ $25) that they can keep.
- Digital food diary: Participants will be asked to take photos of all their food and drink (except water) including the study supplements with their personal mobile computing device (e.g. smart phone, iPad, or similar). Participants will be required to download the free mobile app WhatsApp to send photos with a brief description of the food items. Photos and food description may also be sent to an email address created for this study (food4microbes@sebs.rutgers.edu). The food diary must be kept over the 5-day SPI and wash-out period, day 0 (break day), the 10-day GP-SPI intervention period, and up until the final blood draw on day 11 (17 days total).
- Stool samples: Subjects will be provided with tubes containing 95% ethanol and/or tubes containing 50% glycerol (50% water) along with paper toilet accessories for easy self-collection of fecal samples; each participant will be instructed on use of stool collection materials. Fecal samples will be aliquoted and stored at -80 °C until extraction. Collection of fecal samples in 50% glycerol and immediate freezing will allow culturing of gut bacteria for in vitro experiments.
- Bristol stool scale form: Subjects will be provided with the Bristol stool scale (BSS) form and asked to complete it for stool samples they collect on days -5, 0, 2, 4, 6, 8, and 10 of the study. Stool consistency has been shown to strongly correlate with gut microbiota richness and composition, enterotypes, and bacterial growth rates. Subjects that report at least one bowel movement per day will be recruited for ease of compliance with study protocol. In addition, the BSS form contains an extra column to capture information about menstruation during time of sample collections as this variable could impact metabolite or bacteria profiles .
- Urine samples: Subjects will be provided with sterile collection containers for collection of urine samples on days 2, 4, 6, 8, 10 and asked to keep samples in 4 °C fridge until transport to the laboratory to maintain metabolite stability. Subjects will be asked to bring their samples to the laboratory as soon as possible, within 2-3 days of collection, for processing. Urine samples will be aliquoted and stored at -80 °C until processing for metabolomics studies.
- Blood sample: On day 11 subjects will have a final blood sample drawn. Blood will be used for CMP test and prepared serum will be aliquoted and stored at -80 °C until processing for marker analysis and metabolomics.
Samples will be used for a longitudinal, microbiome-wide association study (MWAS) to identify gut bacteria species/strains that are positively or negatively associated with GP-SPI supplementation. Metabolomics analysis will be performed on collected urine, fecal, and blood samples to identify/quantify known and unknown metabolites. Shotgun metagenomic sequencing will be performed on fecal samples to generate high quality draft genomes for species/strain level identification. These dynamic data sets will serve as input for the MWAS to correlate increasing/decreasing levels of gut bacterial species/strains to increasing/decreasing metabolites. These bacteria-metabolite associations will then be used to infer cause-effect relationships that can be further tested in vitro and in mouse models. We expect that successful completion of these studies will contribute to mechanistic explanations for how dietary polyphenols such as grape PACs alter the gut microbiota and resulting MM to promote metabolic health.
- Conditions
- Mechanisms, Defense
- Being tested
- GP-SPI
- Keywords
- gut microbiome, metabolome, dietary polyphenols, grape, nutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GP-SPIDietary supplement
grape polyphenol-soy protein isolate complex (GP-SPI)
| Study group | Role | What they receive |
|---|---|---|
| GP-SPI intervention | Experimental | 20 g of GP-SPI taken twice per day for 10 days Receives: Dietary Supplement: GP-SPI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut Microbiota Composition
Evaluate the effect of nutritional supplementation with GP-SPI on gut microbiota composition by 16S rRNA amplicon sequencing and analysis
Measured: 16S rRNA amplicon sequencing will be performed on samples collected at baseline (before intervention, day -5), after 5 days of SPI supplementation (day 0), and after 10 days of GP-SPI supplementation (day 10). Total time frame is 17 days.
Secondary outcomes (5)
Comprehensive Metabolic Panel (CMP) Blood Test (ALP, AST, ALT)
Evaluate the effect of GP-SPI on kidney and liver health/function via CMP blood tests ALP, AST, ALT
Measured: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Glucose, Blood Urea Nitrogen, Creatine, Calcium, Bilirubin Total)
Evaluate the effect of GP-SPI on kidney and liver health/function via CMP blood tests Measure glucose, blood urea nitrogen, creatine, calcium, bilirubin total
Measured: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel Blood Test (Anion Gap)
The Anion gap was measured for all 27 participants. The anion gap is a calculation of the difference between the amounts of some negatively charged electrolytes (such as chloride and bicarbonate) and the amount of positively charged electrolytes (such as sodium) in blood. The anion gap reveals whether blood has an imbalance of electrolytes, i.e., blood is too acidic or too basic.
Measured: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Sodium, Potassium, Chloride, Total Carbon Dioxide)
For all 27 participants CMP measured four electrolytes: sodium, potassium, chloride, total carbon dioxide. Electrolytes are minerals that carry an electric charge when they are dissolved in a liquid. These electrolytes in blood control nerve and muscle function and maintain the acid-base balance (pH balance) of blood and water balance.
Sodium: Most sodium comes from food, and kidneys help regulate body's sodium levels.
Potassium: Potassium comes from food and is present in all tissues of body. Bicarbonate: Bicarbonate indicates the amount of carbon dioxide (CO₂) in blood. Chloride: Chloride functions along with sodium, potassium and bicarbonate to control many processes in the body.
Measured: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Protein, Albumin)
Evaluate the effect of GP-SPI on kidney and liver health/function via CMP blood tests
Measured: Samples will be analyzed within one week of blood collection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2019
- Study start28 Jun 2019
- Primary completion20 Dec 2019
- Study completion20 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Mechanisms, DefenseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Longitudinal study
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Diana Roopchand, Ph.D., Rutgers, The State University of New Jersey
- Investigators
- Diana Roopchand, PhD, Principal investigator, Rutgers University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04018066
- Sponsor's protocol ID
- Pro2018002579
- Status last verified
- May 2026
- First submitted
- 8 Jul 2019
- Last updated
- 18 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mezhibovsky E, Wu G, Wu Y, Ning Z, Bacalia K, Sadangi S, Patel R, Poulev A, Duran RM, Macor M, Coyle S, Lam YY, Raskin I, Figeys D, Zhao L, Roopchand DE. Grape polyphenols reduce fasting glucose and increase hyocholic acid in healthy humans: a meta-omics study. NPJ Sci Food. 2025 May 27;9(1):87. doi: 10.1038/s41538-025-00443-6.
PubMed 40425565
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Concord Grape Polyphenol-soy Protein Isolate Complex (GP-SPI) on Gut Microbiota
- ClinicalTrials.gov ID
- NCT04018066
- Acronym / sponsor ID
- Pro2018002579
- Conditions
- Mechanisms, Defense
- Keywords
- gut microbiome, metabolome, dietary polyphenols, grape, nutrition
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Rutgers, The State University of New JerseyUniversity, hospital or other
- Study start
- 28 Jun 2019 (actual)
- Primary completion
- 20 Dec 2019 (actual)
- Study completion
- 20 Dec 2019 (actual)
- First posted
- 12 Jul 2019 (actual)
- Results
- Posted 10 Nov 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall purpose of this study is to evaluate the effect of nutritional supplementation with a well-characterized preparation of Concord grape polyphenol-soy protein isolate (GP-SPI) on the composition of the gut microbiota.
Detailed description
The proposed study will investigate how short-term supplementation with GP-SPI may modify the gut microbial community in healthy participants while monitoring liver and kidney function/health.
Significance:
Biochemical properties of the GP-SPI food ingredient are well-documented and GP-SPI and SPI supplements have been tested extensively in mice. The proposed study is a logical follow up to animal studies, which showed that compared to control mice fed a high-fat diet (HFD) supplemented with SPI alone, mice fed an isocaloric HFD supplemented with GP-SPI exhibited greater resistance to weight gain, adiposity, and glucose intolerance. These effects were accompanied by changes in murine gut microbiota composition, including increased abundance of the microbe Akkermansia muciniphila, associated with metabolic resilience. Similar gut microbiota changes were observed in lean mice fed low-fat diet (LFD) supplemented with GP-SPI.
The B-type proanthocyanidin (PAC) class of polyphenols contained in grape berries, especially skins and seeds, have been associated with health benefits; however, PACs are poorly absorbed and reach high concentration only in the colon raising questions about mechanism(s) of action. Prior studies showed that dietary PACs from grape and cranberry alter the gut microbiota in association with metabolic resilience. PACs are also biotransformed by gut bacteria to yield microbial metabolites (MMs) that may contribute to health benefits.
Research Design and Methods
Prospective participants will be recruited through flyers posted locally on Rutgers University campuses and sent to university email lists. Interested persons will be screened according to inclusion and exclusion criteria.
Enrolled subjects will begin the 17-day study.
Study Procedures
- Thirty subjects will be enrolled.
- Food List: Participants will maintain their usual diet except for a provided list of PAC-rich foods that they will be asked to abstain from for a 5-day wash-out period and during the 10-day intervention. The Food List is provided below. The goal is to have GP-SPI as the main/only source of PAC in the diet for the study period.
- Wash-out and SPI (Day -5 through -1): On day -5 (pre-baseline) before any supplementation, each subject will collect their fecal and urine sample. Each subject will then consume SPI twice a day (provided as pre-weighed packets of 20 g) during a 5-day wash-out period (days -5, -4, -3, -2, and -1). Subjects will be instructed to mix each packet of SPI in 250 mL of water or in a smoothie (recipe example below will be provided) using allowed foods as detailed in instructions and consume once in the morning before breakfast and once in the evening before dinner.
- Day 0: On the following day each subject will collect their baseline (day 0) stool and urine samples. They will have a blood sample drawn by a study nurse. Blood will be used for CMP test and prepared serum will be aliquoted and stored at -80 °C until processing for marker analysis and metabolomics. Analysis of day 0 samples should help isolate any effects due to SPI alone from subsequent samples collected during GP-SPI intervention. On day 0 subjects will drop off urine and stool samples at IFNH and collect GP-SPI packets. On Day 0 participants will also take a break from consuming SPI and will start GP-SPI supplementation on morning of Day 1.
- GP-SPI (Day 1 - 10): Each subject will receive twenty pre-weighed 20 g packets of GP-SPI. On day 1 subjects will be instructed to mix each packet of GP-SPI in 250 mL of water or in smoothie (recipe example will be provided, please see below) using allowed foods as detailed in instructions and consume the GP-SPI mix once in the morning before breakfast and once in the evening before dinner for 10 consecutive days.
- Subjects will be provided with a personal blender for smoothie preparation (value ~ $25) that they can keep.
- Digital food diary: Participants will be asked to take photos of all their food and drink (except water) including the study supplements with their personal mobile computing device (e.g. smart phone, iPad, or similar). Participants will be required to download the free mobile app WhatsApp to send photos with a brief description of the food items. Photos and food description may also be sent to an email address created for this study (food4microbes@sebs.rutgers.edu). The food diary must be kept over the 5-day SPI and wash-out period, day 0 (break day), the 10-day GP-SPI intervention period, and up until the final blood draw on day 11 (17 days total).
- Stool samples: Subjects will be provided with tubes containing 95% ethanol and/or tubes containing 50% glycerol (50% water) along with paper toilet accessories for easy self-collection of fecal samples; each participant will be instructed on use of stool collection materials. Fecal samples will be aliquoted and stored at -80 °C until extraction. Collection of fecal samples in 50% glycerol and immediate freezing will allow culturing of gut bacteria for in vitro experiments.
- Bristol stool scale form: Subjects will be provided with the Bristol stool scale (BSS) form and asked to complete it for stool samples they collect on days -5, 0, 2, 4, 6, 8, and 10 of the study. Stool consistency has been shown to strongly correlate with gut microbiota richness and composition, enterotypes, and bacterial growth rates. Subjects that report at least one bowel movement per day will be recruited for ease of compliance with study protocol. In addition, the BSS form contains an extra column to capture information about menstruation during time of sample collections as this variable could impact metabolite or bacteria profiles .
- Urine samples: Subjects will be provided with sterile collection containers for collection of urine samples on days 2, 4, 6, 8, 10 and asked to keep samples in 4 °C fridge until transport to the laboratory to maintain metabolite stability. Subjects will be asked to bring their samples to the laboratory as soon as possible, within 2-3 days of collection, for processing. Urine samples will be aliquoted and stored at -80 °C until processing for metabolomics studies.
- Blood sample: On day 11 subjects will have a final blood sample drawn. Blood will be used for CMP test and prepared serum will be aliquoted and stored at -80 °C until processing for marker analysis and metabolomics.
Samples will be used for a longitudinal, microbiome-wide association study (MWAS) to identify gut bacteria species/strains that are positively or negatively associated with GP-SPI supplementation. Metabolomics analysis will be performed on collected urine, fecal, and blood samples to identify/quantify known and unknown metabolites. Shotgun metagenomic sequencing will be performed on fecal samples to generate high quality draft genomes for species/strain level identification. These dynamic data sets will serve as input for the MWAS to correlate increasing/decreasing levels of gut bacterial species/strains to increasing/decreasing metabolites. These bacteria-metabolite associations will then be used to infer cause-effect relationships that can be further tested in vitro and in mouse models. We expect that successful completion of these studies will contribute to mechanistic explanations for how dietary polyphenols such as grape PACs alter the gut microbiota and resulting MM to promote metabolic health.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Longitudinal study
| Arm | Type | Receives |
|---|---|---|
| GP-SPI intervention | Experimental | Dietary Supplement: GP-SPI20 g of GP-SPI taken twice per day for 10 days |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy as assessed based on a medical evaluation including a comprehensive metabolic panel (CMP) test with values in normal range, medical history and not presently taking any medication
- Adults between 18 and 35 years
- BMI 18.5 -29.9
- Have at least one bowel movement per day
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Key exclusion criteria (9 listed)
- History/current cancer, rheumatoid arthritis immunologic, renal, hepatic, endocrine, neurologic or heart disease, hypertension, diabetes, GI dysfunction, or CMP test results showing values outside of normal range.
- Cannot provide written informed consent.
- Exposure to any experimental agent or procedure within 30 days of study.
- Pregnancy or breast-feeding
- Taking dietary supplements
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GP-SPIgrape polyphenol-soy protein isolate complex (GP-SPI) | Dietary supplement | GP-SPI intervention |
Primary outcome
Gut Microbiota Composition
Time frame: 16S rRNA amplicon sequencing will be performed on samples collected at baseline (before intervention, day -5), after 5 days of SPI supplementation (day 0), and after 10 days of GP-SPI supplementation (day 10). Total time frame is 17 days.
Evaluate the effect of nutritional supplementation with GP-SPI on gut microbiota composition by 16S rRNA amplicon sequencing and analysis
5 secondary outcomes
Comprehensive Metabolic Panel (CMP) Blood Test (ALP, AST, ALT)
Time frame: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Glucose, Blood Urea Nitrogen, Creatine, Calcium, Bilirubin Total)
Time frame: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel Blood Test (Anion Gap)
Time frame: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Sodium, Potassium, Chloride, Total Carbon Dioxide)
Time frame: Samples will be analyzed within one week of blood collection
Comprehensive Metabolic Panel (CMP) Blood Test (Protein, Albumin)
Time frame: Samples will be analyzed within one week of blood collection
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 40425565Mezhibovsky E, Wu G, Wu Y, Ning Z, Bacalia K, Sadangi S, Patel R, Poulev A, Duran RM, Macor M, Coyle S, Lam YY, Raskin I, Figeys D, Zhao L, Roopchand DE. Grape polyphenols reduce fasting glucose and increase hyocholic acid in healthy humans: a meta-omics study. NPJ Sci Food. 2025 May 27;9(1):87. doi: 10.1038/s41538-025-00443-6.
- peer reviewed and published studyLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Mechanisms, Defense
RecruitingObservational study
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
Host Defense Mechanisms
Not yet recruitingObservational study
Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With Depression
Major Depressive Disorder (MDD)
Not yet recruitingObservational study
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.
Single Cell Sequencing Technology, Gene Expression Profiling
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Diana Roopchand, PhD principal investigator
Rutgers University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GP-SPI in people with Mechanisms, Defense, run by Rutgers, The State University of New Jersey at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut Microbiota Composition (time frame: 16S rRNA amplicon sequencing will be performed on samples collected at baseline (before intervention, day -5), after 5 days of SPI supplementation (day 0), and after 10 days of GP-SPI supplementation (day 10). Total time frame is 17 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04018066, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.